Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AIK-5
- Development stage
- Preclinical
- Lead developer
- Allinky Biopharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AIK-5 is a small molecule therapeutic drug developed by Allinky Biopharma SL. It functions as an allosteric inhibitor of Calcineurin (CaN) and Nuclear Factor of Activated T-cells cytoplasmic 1 (NFATC1). By inhibiting these key proteins, AIK-5 aims to suppress T-cell activation and the subsequent expression of pro-inflammatory genes. This mechanism of action positions AIK-5 as a potential treatment for immune system diseases and other related conditions.
02
Targets
CN (Calcineurin)NFAT (NFAT family)
Beyond the preview
Go deeper on AIK-5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AIK-5.